{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T23:37:03Z","timestamp":1771544223977,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,10,5]],"date-time":"2015-10-05T00:00:00Z","timestamp":1444003200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1038\/bmt.2015.236","type":"journal-article","created":{"date-parts":[[2015,10,5]],"date-time":"2015-10-05T13:42:49Z","timestamp":1444052569000},"page":"372-376","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["A randomized phase II study of stem cell mobilization with cyclophosphamide+G-CSF or G-CSF alone after lenalidomide-based induction in multiple myeloma"],"prefix":"10.1038","volume":"51","author":[{"given":"R","family":"Silvennoinen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Anttila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"S\u00e4ily","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Lundan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Heiskanen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T M","family":"Siitonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Kakko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Putkonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Ollikainen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V","family":"Ter\u00e4v\u00e4","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Kutila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Launonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"R\u00e4s\u00e4nen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Siki\u00f6","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Suominen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Bazia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Kananen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Selander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Kuittinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Remes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Jantunen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,10,5]]},"reference":[{"key":"BFbmt2015236_CR1","doi-asserted-by":"publisher","first-page":"5436","DOI":"10.1182\/blood-2009-07-204651","volume":"114","author":"AK Stewart","year":"2009","unstructured":"Stewart AK, Richardson PG, San Miguel JF . How I treat multiple myeloma in younger patients. Blood 2009; 114: 5436\u20135443.","journal-title":"Blood"},{"key":"BFbmt2015236_CR2","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1182\/blood-2014-03-544759","volume":"124","author":"MA Gertz","year":"2014","unstructured":"Gertz MA, Dingli D . How we manage autologous stem cell transplantation for patients with multiple myeloma. Blood 2014; 124: 882\u2013890.","journal-title":"Blood"},{"key":"BFbmt2015236_CR3","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1200\/JCO.1998.16.4.1547","volume":"16","author":"KR Desikan","year":"1998","unstructured":"Desikan KR, Barlogie B, Jagannath S, Vesole DH, Siegel D, Fassas A et al. Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma. J Clin Oncol 1998; 16: 1547\u20131553.","journal-title":"J Clin Oncol"},{"key":"BFbmt2015236_CR4","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/j.bbmt.2012.01.008","volume":"18","author":"D Sheppard","year":"2012","unstructured":"Sheppard D, Bredeson C, Allan D, Tay J . Systematic review of randomized controlled trials of hematopoietic stem cell mobilization strategies for autologous transplantation for hematologic malignancies. Biol Blood Marrow Transplant 2012; 18: 1191\u20131203.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2015236_CR5","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/sj.bmt.1702879","volume":"27","author":"O Fitoussi","year":"2001","unstructured":"Fitoussi O, Perreau V, Boiron JM, Bouzigon E, Cony-Makhoul P, Pigneux A et al. A comparison of toxicity following two different doses of cyclophosphamide for mobilization of peripheral blood progenitor cells in 116 multiple myeloma patients. Bone Marrow Transplant 2001; 27: 837\u2013842.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2015236_CR6","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/sj.bmt.1703840","volume":"31","author":"E Jantunen","year":"2003","unstructured":"Jantunen E, Putkonen M, Nousiainen T, Pelliniemi T-T, Mahlam\u00e4ki E, Remes K . Low-dose or intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor for progenitor cell mobilization in patients with multiple myeloma. Bone Marrow Transplant 2003; 31: 347\u2013351.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2015236_CR7","doi-asserted-by":"publisher","first-page":"384","DOI":"10.3816\/CLM.2006.n.014","volume":"6","author":"D Dingli","year":"2006","unstructured":"Dingli D, Nowakowski GS, Dispenzieri A, Lacy MQ, Hayman S, Litzov MR et al. Cyclophosphamide mobilization does not improve outcome in patients receiving stem cell transplantation for multiple myeloma. Clin Lymphoma Myeloma 2006; 6: 384\u2013388.","journal-title":"Clin Lymphoma Myeloma"},{"key":"BFbmt2015236_CR8","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1080\/14653240701452800","volume":"9","author":"DK Hiwase","year":"2007","unstructured":"Hiwase DK, Bollard G, Hiwase S, Bailey M, Muirhead J, Schwarer AP . Intermediate-dose CY and G-CSF more efficiently mobilize adequate numbers of PBSC for tandem autologous PBSC transplantation compared with low-dose CY in patients with multiple myeloma. Cytotherapy 2007; 9: 539\u2013547.","journal-title":"Cytotherapy"},{"key":"BFbmt2015236_CR9","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1182\/blood.V118.21.4127.4127","volume":"118","author":"WA Bacon","year":"2011","unstructured":"Bacon WA, Long GD, Rizzieri DA, Horwitz ME, Chute JP, Sullivan KM et al. Impact of high-dose cyclophosphamide on the outcome of autologous stem cell transplant in patients with newly diagnosed multiple myeloma [abstract]. (ASH Annual Meeting Abstracts). Blood 2011; 118: 4127.","journal-title":"Blood"},{"key":"BFbmt2015236_CR10","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1038\/sj.leu.2404801","volume":"21","author":"S Kumar","year":"2007","unstructured":"Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Gastineau DA et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 2007; 21: 2035\u20132042.","journal-title":"Leukemia"},{"key":"BFbmt2015236_CR11","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1038\/sj.leu.2405035","volume":"22","author":"A Mazumder","year":"2008","unstructured":"Mazumder A, Kaufman J, Niesvizky R, Lonial S, Vesole D, Jagannath S . Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients. Leukemia 2008; 22: 1280\u20131281.","journal-title":"Leukemia"},{"key":"BFbmt2015236_CR12","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1038\/sj.leu.2405100","volume":"22","author":"H Paripati","year":"2008","unstructured":"Paripati H, Stewart AK, Cabou S, Dueck A, Zepeda VJ, Pirooz N et al. Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. Leukemia 2008; 22: 1282\u20131284.","journal-title":"Leukemia"},{"key":"BFbmt2015236_CR13","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.bbmt.2009.02.011","volume":"15","author":"U Popat","year":"2009","unstructured":"Popat U, Saliba R, Thandi R, Hosing C, Qazilbash M, Anderlini P et al. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant 2009; 15: 718\u2013723.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2015236_CR14","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","volume":"116","author":"PG Richardson","year":"2010","unstructured":"Richardson PG, Weller W, Lonial S, Jakubowiak AJ, Jagannath S, Raje NS et al. Lenalidomide, bortezomib and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010; 116: 679\u2013686.","journal-title":"Blood"},{"key":"BFbmt2015236_CR15","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1200\/JCO.2013.54.8164","volume":"32","author":"M Roussel","year":"2014","unstructured":"Roussel M, Lauwers-Cances V, Robillard N, Hulin C, Leleu X, Benboubker L et al. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by Intergroupe Francophone du Myelome. J Clin Oncol 2014; 32: 2712\u20132718.","journal-title":"J Clin Oncol"},{"key":"BFbmt2015236_CR16","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.bbmt.2008.04.008","volume":"14","author":"T Mark","year":"2008","unstructured":"Mark T, Stern J, Furst JR, Jayabalan D, Zafar F, LaRow A et al. Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma. Biol Blood Marrow Transplant 2008; 14: 795\u2013798.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2015236_CR17","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1038\/leu.2011.131","volume":"25","author":"F Cavallo","year":"2011","unstructured":"Cavallo F, Bringhen S, Milone G, Ben-Yehuda D, Nagler A, Calabrese E et al. Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy. Leukemia 2011; 25: 1627\u20131631.","journal-title":"Leukemia"},{"key":"BFbmt2015236_CR18","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1038\/bmt.2012.60","volume":"47","author":"LJ Costa","year":"2012","unstructured":"Costa LJ, Abbas J, Hogan KR, Kramer C, McDonald K, Butcher CD et al. Growth factor plus preemptive ('just-in-time') plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure. Bone Marrow Transplant 2012; 47: 1403\u20131408.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2015236_CR19","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1182\/blood-2009-04-205013","volume":"114","author":"S Kumar","year":"2009","unstructured":"Kumar S, Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W et al. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood 2009; 114: 1729\u20131735.","journal-title":"Blood"},{"key":"BFbmt2015236_CR20","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.bbmt.2013.10.013","volume":"20","author":"S Giralt","year":"2014","unstructured":"Giralt S, Costa L, Schriber J, DiPersio J, Maziarz R, McCarty J et al. Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. Biol Blood Marrow Transplant 2014; 20: 295\u2013308.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2015236_CR21","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.bbmt.2014.05.003","volume":"20","author":"HK Duong","year":"2014","unstructured":"Duong HK, Savani BN, Copelan E, Devine S, Costa LJ, Wingard JR et al. Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: Guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2014; 20: 1262\u20131273.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2015236_CR22","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1182\/blood-2008-08-174946","volume":"113","author":"JF DiPersio","year":"2009","unstructured":"DiPersio JF, Stadtmauer EA, Nademanee A, Micallef INM, Stiff PJ, Kaufman JL et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009; 113: 5720\u20135726.","journal-title":"Blood"},{"key":"BFbmt2015236_CR23","doi-asserted-by":"publisher","first-page":"e255","DOI":"10.1038\/bcj.2014.79","volume":"4","author":"RE Clark","year":"2014","unstructured":"Clark RE, Bell J, Clark JO, Braithwaite B, Vithanarachchi U, McGinnity N et al. Plerixafor is superior to conventional chemotherapy for first-line stem cell mobilization, and is effective even in heavily pretreated patients. Blood Cancer J 2014; 4: e255.","journal-title":"Blood Cancer J"},{"key":"BFbmt2015236_CR24","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/bmt.2014.39","volume":"49","author":"M Mohty","year":"2014","unstructured":"Mohty M, H\u00fcbel K, Kr\u00f6ger N, Aljurf A, Apperley J, Basak GW et al. Autologous haematopoietic stem cell mobilization in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2014; 49: 865\u2013872.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2015236_CR25","unstructured":"Stichting Hemato-Oncologie voor Volwassenen Nederland. Study to compare VMP with HDM followed by VRD consolidation and lenalidomide maintenance in patients with newly diagnosed multiple myeloma (HO95). Available at http:\/\/clinicaltrials.gov NCT01208766."},{"key":"BFbmt2015236_CR26","unstructured":"Richardson PG . Dana-Farber Cancer Institute. Randomized trial of lenalidomide, bortezomib, dexamethasone vs. high-dose treatment with SCT in MM patients up to age 65 (DFCI 10-106). Available at http:\/\/clinicaltrials.gov . NCT01208662."},{"key":"BFbmt2015236_CR27","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1038\/leu.2010.82","volume":"24","author":"P Moreau","year":"2010","unstructured":"Moreau P, Hulin C, Marit G, Gaillon D, Facon T, Lenain P et al. Stem cell collection in patients with de novo multiple myeloma treated with the combination of bortezomib and dexamethasone before autologous stem cell transplantation according to IFM 2005-01 trial. Leukemia 2010; 24: 1233\u20131235.","journal-title":"Leukemia"},{"key":"BFbmt2015236_CR28","doi-asserted-by":"publisher","first-page":"3833","DOI":"10.1182\/blood-2004-03-0828","volume":"105","author":"KR Koh","year":"2005","unstructured":"Koh KR, Janz M, Mapara MY, Lemke B, Stirling D, D\u00f6rken B et al. Immunomodulatory derivative of thalidomide (IMiD CC-4407) induces a shift in lineage commitment by suppressing erythropoiesis and promoting myelopoiesis. Blood 2005; 105: 3833\u20133840.","journal-title":"Blood"},{"key":"BFbmt2015236_CR29","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1182\/blood-2009-05-221077","volume":"115","author":"R Pal","year":"2010","unstructured":"Pal R, Monaghan SA, Hassett AC, Mapara MY, Schafer P, Roodman GD et al. Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia. Blood 2010; 115: 605\u2013614.","journal-title":"Blood"},{"key":"BFbmt2015236_CR30","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1038\/leu.2012.323","volume":"27","author":"S Li","year":"2013","unstructured":"Li S, Fu J, Ma H, Mapara MY, Lentzsch S . Lenalidomide-induced upregulation of CXCR4 in CD34+ hematopoietic cells, a potential mechanism of decreased hematopoietic progenitor mobilization. Leukemia 2013; 27: 1407\u20131411.","journal-title":"Leukemia"},{"key":"BFbmt2015236_CR31","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.blre.2014.01.001","volume":"28","author":"RK Hopman","year":"2014","unstructured":"Hopman RK, DiPersio JF . Advances in stem cell mobilization. Blood Rev 2014; 28: 31\u201340.","journal-title":"Blood Rev"},{"key":"BFbmt2015236_CR32","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1158\/1078-0432.CCR-12-1429","volume":"19","author":"R Niesvizky","year":"2013","unstructured":"Niesvizky R, Mark TM, Ward M, Jayabalan DS, Pearse RN, Manco M et al. Overcoming the response plateau in multiple myeloma: a novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilization. Clin Cancer Res 2013; 19: 1534\u20131546.","journal-title":"Clin Cancer Res"},{"key":"BFbmt2015236_CR33","unstructured":"A pilot study of peripheral blood hematopoietic stem cell mobilization with the combination of bortezomib and G-CSF in multiple myeloma and non-Hodgkin\u2019s lymphoma patients. Available at http:\/\/clinicaltrials.gov NCT02037256."},{"key":"BFbmt2015236_CR34","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/bjh.12139","volume":"160","author":"R Silvennoinen","year":"2013","unstructured":"Silvennoinen R, Kairisto V, Pelliniemi T-T, Putkonen M, Anttila P, S\u00e4ily M et al. Assessment of molecular remission rate after bortezomib plus dexamethasone induction treatment and autologous stem cell transplantation in newly diagnosed multiple myeloma patients. Br J Haematol 2013; 160: 561\u2013564.","journal-title":"Br J Haematol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bmt2015236.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bmt2015236","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bmt2015236.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:42:21Z","timestamp":1684417341000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2015236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,5]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["BFbmt2015236"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2015.236","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,5]]},"assertion":[{"value":"17 June 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RS has received a research grant from Celgene and Janssen and honoraria from Genzyme and Sanofi. EJ has received honoraria from Genzyme and Sanofi and has participated in an EU Leadership meeting organized by Genzyme as well as a Medical Advisory Board meeting organized by Genzyme. KR has received Advisory Board honoraria from Celgene, Janssen and Roche. MP has received Advisory Board honoraria from Amgen and Celgene. KK has received honoraria from Amgen, Roche and Fresenius and educational travel grants from Amgen and Hospira. AR has participated in Advisory Boards organized by Amgen and Roche. MS has received educational travel grants from Celgene, Genzyme and Pfizer. KL has received educational travel grants from Celgene, Mundipharma and Novartis. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}